to evaluate the influence of the angiotensin-converting-enzyme inhibitor enalapril ( 2.5 to 40 mg per day ) on the prognosis of severe congestive heart failure ( new york heart association [ nyha ] functional class iv ) , we randomly assigned 253 patients in a double-blind study to receive either placebo ( n = 126 ) or enalapril ( n = 127 ) .
C0018802
congestive heart
C0014025
enalapril